Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study
The Oncologist · 10.03.2025 · 30 (3)
DOI: 10.1093/oncolo/oyaf018 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 31.03.2025. Verfasst von Takane Watanabe und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 104-0045, 5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Head and Neck Neoplasms, Neoplasm Recurrence, Local, Nivolumab. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Platinum and anti-PD-1 antibodies are the front-line systemic therapy for recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). However, limited data are available on clinical outcomes and appropriate regimens for patients with RM-HNSCC following treatment failure with these agents. Patients and methods We retrospectively analyzed the clinical data of patients with RM-HNSCC from 10 Japanese institutions in whom platinum and nivolumab treatment failed.
Results
Of the 480 patients included in the study, 236 were treated with the best supportive care and had a median overall survival of 3.1 months. The remaining 244 patients received salvage-line chemotherapy, which was paclitaxel + cetuximab in 72 (30%), paclitaxel or docetaxel in 89 (36%), and tegafur/gimeracil/oteracil in 48 (20%); the respective objective response rates were 54.9%, 27.9%, and 25.5%, with median progression-free survival of 5.4 months and median overall survival of 13.0 months. Multivariable analysis identified disease stabilization or response on prior nivolumab and paclitaxel + cetuximab as salvage-line chemotherapy to be associated with encouraging progression-free and overall survival.
Conclusion
This study sheds light on clinical outcomes and prognostic factors in patients with RM-HNSCC after failure of platinum and anti-PD-1 antibody therapy. The findings provide essential baseline data for future therapeutic development in salvage-line settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 104-0045, 5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan.
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo 160-0016, Japan.
- Otorhinolaryngology/Head and Neck Surgery, Nagasaki University Hospital, Nagasaki 852-8501, Japan.
- Otorhinolaryngology/Head and Neck Surgery, Tokai University Hospital, Isehara 259-1193, Japan.
- Department of Medical Oncology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
- Otorhinolaryngology, Head and Neck Surgery, Hokkaido University Hospital, Sapporo 060-8648, Japan.
ORCID-Profile: Takane Watanabe, Kengo Nagashima, Tomoya Yokota, Naomi Kiyota, Yasuyoshi Sato, Shunji Takahashi, Shigenori Kadowaki, Yoshitaka Honma
Zitieren
APA
Watanabe, T., Oka, H., Nagashima, K., Nishi, H., Kumai, Y., Iijima, H., Okami, K., Shimizu, Y., Kano, S., Ito, K., Yamazaki, T., Takahashi, H., Oridate, N., Yokota, T., Koyama, T., Kiyota, N., Sato, Y., Takahashi, S., Kato, K., …, & Honma, Y. (2025). Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study. The Oncologist, 30(3). https://doi.org/10.1093/oncolo/oyaf018
Vancouver
Watanabe T, Oka H, Nagashima K, Nishi H, Kumai Y, Iijima H, et al. Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study. The Oncologist. 2025;30(3). doi:10.1093/oncolo/oyaf018
BibTeX
@article{Watanabe2025,
author = {Watanabe, Takane and Oka, Hiroki and Nagashima, Kengo and Nishi, Hideaki and Kumai, Yoshihiko and Iijima, Hiroaki and Okami, Kenji and Shimizu, Yasushi and Kano, Satoshi and Ito, Kazue and Yamazaki, Tomoko and Takahashi, Hideaki and Oridate, Nobuhiko and Yokota, Tomoya and Koyama, Taiji and Kiyota, Naomi and Sato, Yasuyoshi and Takahashi, Shunji and Kato, Kyoko and Kadowaki, Shigenori and Honma, Yoshitaka},
title = {Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {3},
doi = {10.1093/oncolo/oyaf018}
}
EUVIMED